Inside cancer - public lecture

Investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma

Pembrolizumab showed clinical benefit in malignant pleural mesothelioma

Chk1 inhibition combined with standard dose gemcitabine may be safe and effective

Updated results on phase III CLL trial shows 90% response rate using ibrutinib

Developing treatments for indolent non hodgkin lymphoma

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

BRAF 'behind the scenes' in melanoma: A scientific story of discovery